Chemed Corporation $CHE Shares Acquired by KBC Group NV

KBC Group NV lifted its holdings in shares of Chemed Corporation (NYSE:CHE) by 395.4% during the second quarter, HoldingsChannel.com reports. The fund owned 3,101 shares of the company’s stock after purchasing an additional 2,475 shares during the quarter. KBC Group NV’s holdings in Chemed were worth $1,510,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Creekmur Asset Management LLC acquired a new stake in Chemed during the 2nd quarter worth $28,000. SVB Wealth LLC purchased a new stake in shares of Chemed in the first quarter valued at about $30,000. WPG Advisers LLC acquired a new stake in shares of Chemed during the first quarter worth about $32,000. Parkside Financial Bank & Trust grew its holdings in shares of Chemed by 86.3% during the second quarter. Parkside Financial Bank & Trust now owns 95 shares of the company’s stock worth $46,000 after buying an additional 44 shares during the last quarter. Finally, Geneos Wealth Management Inc. increased its position in Chemed by 330.4% in the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after acquiring an additional 76 shares during the period. Hedge funds and other institutional investors own 95.85% of the company’s stock.

Chemed Price Performance

Chemed stock opened at $435.18 on Monday. The stock’s 50 day moving average price is $443.97 and its 200 day moving average price is $482.84. Chemed Corporation has a 1-year low of $408.42 and a 1-year high of $623.60. The company has a market cap of $6.16 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 2.69 and a beta of 0.43.

Chemed (NYSE:CHE) last released its earnings results on Tuesday, October 28th. The company reported $5.27 EPS for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). The business had revenue of $624.90 million during the quarter, compared to analyst estimates of $626.04 million. Chemed had a net margin of 11.02% and a return on equity of 25.89%. Chemed’s revenue was up 3.1% compared to the same quarter last year. During the same period last year, the business posted $5.64 EPS. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. On average, equities research analysts anticipate that Chemed Corporation will post 21.43 EPS for the current fiscal year.

Chemed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Monday, November 17th will be issued a dividend of $0.60 per share. The ex-dividend date of this dividend is Monday, November 17th. This represents a $2.40 dividend on an annualized basis and a yield of 0.6%. Chemed’s payout ratio is currently 12.69%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Royal Bank Of Canada decreased their price objective on Chemed from $589.00 to $572.00 and set an “outperform” rating for the company in a research report on Monday, November 10th. Oppenheimer cut their price target on Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a research note on Thursday, July 31st. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 30th. Weiss Ratings reissued a “hold (c-)” rating on shares of Chemed in a research note on Wednesday, October 8th. Finally, Jefferies Financial Group upgraded shares of Chemed from a “hold” rating to a “buy” rating and raised their target price for the stock from $490.00 to $550.00 in a research note on Tuesday, September 2nd. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $574.25.

Insider Activity

In other Chemed news, Director Patrick P. Grace sold 150 shares of the stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $463.39, for a total value of $69,508.50. Following the completion of the transaction, the director directly owned 3,397 shares of the company’s stock, valued at approximately $1,574,135.83. This trade represents a 4.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Kevin J. Mcnamara sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $461.28, for a total value of $1,383,840.00. Following the sale, the chief executive officer directly owned 96,197 shares in the company, valued at $44,373,752.16. This trade represents a 3.02% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 3.29% of the company’s stock.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.